Select Page

South Delhi Pharma, New Delhi, India

TUKYSA ™ (tucatinib) tablets, for oral use.

SDP are here to serve you through the quality pharmaceutical products as per your needs. Established in the year 1996, we have earned a global reputation in the market. Owing to superior quality widest range of Anti Cancer medicines.

TUKYSA is a prescription medicine. TUKYSA is used to treat breast cancer
INDICATIONS AND USAGE
TUKYSA is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting
DOSAGE FORMS & STRENGTHS
Tablets: 50 mg and 150 mg
Manufactured By: Seattle Genetics
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “TUKYSA ™ (tucatinib) tablets” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Category:

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

4 + 13 =

Tucatinib (INN), sold under the brand name Tukysa, is a small molecule inhibitor of HER2 for the treatment of HER2-positive breast cancer. It was developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly Oncothyreon, subsequently part of Seattle Genetics).

Tucatinib was approved for medical use in Australia in August 2020.

ucatinib is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

Reviews

There are no reviews yet.

Be the first to review “TUKYSA ™ (tucatinib) tablets, for oral use.”

Your email address will not be published. Required fields are marked *